Pre-Test Optimizing Outcomes in IBD: The Role of Therapeutic Drug Monitoring and Precision Medicine Pre-Test Approximately _____ of patients discontinue anti-TNF therapy for primary non-response. 20%-30% 30%-40% 40%-50% 50%-60% Unsure The method of __________ offers objective data to expedite therapy adjustments for individual IBD patients and has demonstrated efficacy in maintaining clinical remission. Enzyme-linked immunosorbent assay analysis of anti-drug antibodies Homogenous mobility shift assay analysis of serum drug concentrations Precision-guided dosing (Bayesian forecasting) Radioimmunoassay analysis of plasma drug concentrations Unsure Which of the following is a 2021 expert-recommended use of TDM? Proactive TDM is recommended for individuals with IBD on anti-TNFa therapy Proactive TDM is recommended for individuals with IBD on any biologic therapy Reactive TDM is recommended for individuals with IBD on anti-TNFa therapy Reactive TDM is recommended for individuals with IBD on any biologic therapy Unsure How confident are you in your ability to implement novel tools for TDM in your clinical practice? Very confident Confident Somewhat confident Not very confident Not at all confident
